Abi Millar

All articles by Abi Millar

1. FDA greenlight for esketamine sheds light on ketamine’s potential

   On 5 March 2019, the US Food and Drug Administration (FDA) approved Spravato (esketamine) nasal spray for patients with treatment-resistant…
   Read More…

   13 Jun
2. Inside Italy’s pharmaceutical industry

   In July 2018, Italy officially overtook Germany as Europe’s leading pharmaceutical producer. It had generated €31.2bn in pharmaceutical value, compared…
   Read More…

   2 May
3. Snake venom in pharma: access to antivenom is a topic that needs attention

   Snake bites are a major public health issue in many parts of the world. It is thought that over five…
   Read More…

   24 Apr
4. Developing a new class of cancer combo drugs

   It’s a familiar problem within oncology: how can we develop treatments that kill cancer cells while leaving healthy tissue unscathed?…
   Read More…

   2 Feb
5. Is a lack of female participants skewing heart disease trial results?

   Heart disease is a major health concern for both men and women. According to the British Heart Foundation, there are…
   Read More…

   20 Nov
6. Using AI to personalise drug combination therapy

   Multiple myeloma is a difficult cancer to treat. A form of blood cancer, it is considered incurable, but the available…
   Read More…

   15 Nov
7. Manufacturing personalised meds: what needs to change?

   The age of personalised medicine – once discussed in purely hypothetical terms – is now very much upon us. With…
   Read More…

   13 Nov
8. Cancer trials: making the most of biomarkers

   Over the last two decades, we have seen a surge of targeted treatments for cancer. Beginning with Herceptin (which is…
   Read More…

   5 Nov
9. Gene and cell therapies: making manufacturing work

   Gene and cell therapies are two of the fastest emerging areas of medicine. Comprising techniques such as gene editing and…
   Read More…

   3 Oct
10. Cannabinoids breakthrough signals hope for epilepsy treatment

    On 25h June 2018, the US Food and Drug Administration (FDA) approved Epidiolex, a cannabinoid-based medicine for treating seizures in…
    Read More…

    3 Sep